(PRESS RELEASE) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), a global enterprise with core competencies in the life science fields of healthcare and nutrition and and one of the largest pharmaceutical companies in the world, has announced … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Spain
Tagged analytical development, Asklepios BioPharmaceutical, Bayer, Certified Good Manufacturing Practices (cGMP), commercial manufacturing, contract development and manufacturing organization (CDMO), European Medicines Agency (EMA), gene therapies, Javier García, Jimmy Vanhove, manufacturing capacity, quality control labs, recombinant adeno-associated virus (rAAV), science and technology (MSAT), single-use bioreactors, Spanish Agency for Medicines and Medical Devices (AEMPS), Viralgen Vector Core
(COMUNICADO DE PRENSA) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), una empresa global con competencias básicas en los campos de las ciencias biológicas de la salud y la nutrición y una de las compañías farmacéuticas más grandes … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Spain
Tagged Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Agencia Europea del Medicamento (EMA), Asklepios BioPharmaceutical, Bayer, biorreactores de un solo uso, Buenas Prácticas de Fabricación Certificadas (cGMP), capacidad de fabricación, ciencia y tecnología (MSAT), desarrollo analítico, fabricación comercial, Javier García, Jimmy Vanhove, laboratorios de control de calidad, organización de fabricación y desarrollo por contrato (CDMO), terapias génicas, Viralgen Vector Core, virus recombinante adenoasociado ( rAAV)
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?